Issue |
BIO Web Conf.
Volume 152, 2025
International Conference on Health and Biological Science (ICHBS 2024)
|
|
---|---|---|
Article Number | 01001 | |
Number of page(s) | 10 | |
Section | Dense Matter | |
DOI | https://doi.org/10.1051/bioconf/202515201001 | |
Published online | 20 January 2025 |
Comparison of effectiveness of aspirin, clopidogrel and cilostazol monotherapy treatment in ischaemic stroke
1 Pharmacy Departemen, Faculty of Health, Universitas Harapan Bangsa, Central Java, Indonesia
2 Pharmacy Departemen, Faculty of Health, Universitas Al-Irsyad Cilacap, Central Java, Indonesia
* Corresponding author: khamdiyah@uhb.ac.id
Stroke is the third most common cause of disability and the second most common cause of death globally. Between 1990 and 2019, its prevalence increased by 70%. The prevalence of stroke increased from 7% in 2013 to 10.9% in 2018 in Indonesia. Because antiplatelet medication does not improve platelet aggregation, ischemic stroke patients have significant death and disability rates. The efficacy of cilostazol, clopidogrel, and aspirin in ischemic stroke patients is compared in this study. 205 patients who satisfied the inclusion criteria from 919 stroke cases at RSUD Margono Soekarjo in 2023 were the subjects of a cross-sectional retrospective design using purposive sampling. The Kruskal-Wallis test and mean difference tests were used to examine the results of the therapy. Outperforming aspirin and cilostazol, clopidogrel (75 mg) were the most widely used medication (38.6%) and produced the best results, considerably enhancing PT (1 s), APTT (0.872 s), and lowering leukocytes (2.956) and platelets (3.035). Significant variations in leukocyte (p=0.045) and platelet (p=0.040) levels were found using statistical tests. When it came to enhancing coagulation markers and lowering inflammation, clopidogrel proved to be a more effective therapy option for ischemic stroke.
© The Authors, published by EDP Sciences, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.